Research programme: GPCR modulators - Heptares Therapeutics

Drug Profile

Research programme: GPCR modulators - Heptares Therapeutics

Alternative Names: anti-PAR2 mAb - Heptares Therapeutics; calcitonin gene-related peptide (CGRP) modulators - Heptares Therapeutics; CNS disorder therapeutics - Heptares Therapeutics; M1/M4 agonist - Heptares Therapeutics; mGlus NAM - Heptares Therapeutics; muscarinic M1 agonists - Heptares Therapeutics; Orexin OX1 receptor antagonist - Heptares Therapeutics; Orexin OX2 agonists - Heptares Therapeutics

Latest Information Update: 07 Sep 2016

Price : $50

At a glance

  • Originator Heptares Therapeutics
  • Developer Allergan; Heptares Therapeutics; Medical Research Council; Shire
  • Class Antibodies; Small molecules
  • Mechanism of Action Adenosine A2 receptor antagonists; Adenosine A2A receptor antagonists; Calcitonin gene-related peptide antagonists; G protein-coupled receptor modulators; Metabotropic glutamate receptor 5 modulators; Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists; Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists; PAR 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cognition disorders; Obsessive-compulsive disorders; Parkinson's disease; Psychotic disorders
  • Research Anxiety disorders; Atopic dermatitis; Autistic disorder; CNS disorders; Depressive disorders; Drug abuse; Migraine; Sleep disorders; Unspecified

Most Recent Events

  • 07 Sep 2016 Early research in Atopic dermatitis in United Kingdom (unspecified route) before September 2016 (Heptares Therapeutics pipeline, September 2016)
  • 06 Sep 2016 Preclinical trials in Obsessive-compulsive disorders in United Kingdom (unspecified route)
  • 18 Apr 2016 Preclinical trials in Psychotic disorders in United Kingdom (unspecified route) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top